{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=2", "query": { "intervention": "Phase 1b", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-03T05:46:24.226Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04938817", "title": "Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "coformulation pembrolizumab/quavonlimab", "type": "BIOLOGICAL" }, { "name": "lenvatinib", "type": "DRUG" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "coformulation favezelimab/pembrolizumab", "type": "BIOLOGICAL" }, { "name": "R-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2021-08-19", "completion_date": "2029-12-10", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 12, "location_summary": "Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04938817" }, { "nct_id": "NCT06873789", "title": "A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "INCB177054", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2025-06-30", "completion_date": "2026-07-29", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 9, "location_summary": "Los Angeles, California • Panorama City, California • Gainesville, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Panorama City", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06873789" }, { "nct_id": "NCT03297463", "title": "Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Pulmonary Metastases", "Hepatic Metastases", "Brain Metastases" ], "interventions": [ { "name": "Interleukin-2 & Ipilimumab (P-Ib)", "type": "DRUG" }, { "name": "Interleukin-2 & Ipilimumab (P-II)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 0, "start_date": "2018-01-31", "completion_date": "2020-02-01", "has_results": false, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297463" }, { "nct_id": "NCT05413421", "title": "Study of ORIC-944 in Patients With Metastatic Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "ORIC-944", "type": "DRUG" }, { "name": "Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets", "type": "DRUG" }, { "name": "Apalutamide (Erleada™) 60 mg or 240 mg tablets", "type": "DRUG" }, { "name": "Darolutamide (Nubeqa®) 300 mg tablets", "type": "DRUG" }, { "name": "Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 275, "start_date": "2022-06-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 20, "location_summary": "Colorado Springs, Colorado • Plantation, Florida • Arlington Heights, Illinois + 17 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Plantation", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Lake Barrington", "state": "Illinois" }, { "city": "Jeffersonville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05413421" }, { "nct_id": "NCT02538614", "title": "Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "BI 836826", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2015-12-29", "completion_date": "2017-07-05", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 2, "location_summary": "Columbus, Ohio • Salt Lake City, Utah", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538614" }, { "nct_id": "NCT02335814", "title": "First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "FLX925", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RAPT Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-04-08", "completion_date": "2017-05-03", "has_results": false, "last_update_posted_date": "2018-02-09", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335814" }, { "nct_id": "NCT06736717", "title": "Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2025-02", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06736717" }, { "nct_id": "NCT03465540", "title": "Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Acute Myeloid Leukemia", "Non-Hodgkins Lymphoma", "Myelodysplastic Syndrome", "AML", "MDS", "NHL" ], "interventions": [ { "name": "AMG 397", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2018-08-17", "completion_date": "2019-07-25", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03465540" }, { "nct_id": "NCT00717340", "title": "A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "tivozanib (AV-951) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2009-02", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00717340" }, { "nct_id": "NCT03190174", "title": "Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ewing Sarcoma", "PEComa", "Epithelioid Sarcoma", "Desmoid Tumor", "Chordoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Classical Hodgkin Lymphoma", "Colorectal Cancer", "MTOR Activating Mutation" ], "interventions": [ { "name": "Nab-Rapamycin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 34, "start_date": "2017-08-24", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-09-03T05:46:24.226Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190174" } ] }